Changes in the vasodilatory response to methyl-nicotinate in response to S-citalopram [escitalopram] treatment in social phobia patients.

Trial Profile

Changes in the vasodilatory response to methyl-nicotinate in response to S-citalopram [escitalopram] treatment in social phobia patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2011 Planned end date changed from 1 Dec 2009 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top